"Luyten_2015-1088R.1_with_sbd_comments.docx" 12/15; lw 12/21; lw to dl 12/21; dl to sd 12/23; sd 12/23; lw to au 12/28; [6] Polio has been eliminated from the United States and Europe. [2] Despite these historical successes, vaccination is not just a story from the past. Stanley Plotkin and colleagues enumerated twenty-two diseases and infections for which effective vaccines exist but also forty-seven "Luyten_2015-1088R.1_with_sbd_comments.docx" 12/15; lw 12/21; lw to dl 12/21; dl to sd 12/23; sd 12/23; lw to au 12/28; others for which sufficiently effective vaccines are currently not available. [7] Infectious diseases, many of which are vaccine preventable, remain a leading cause of worldwide mortality. Perhaps an even greater issue is antibiotic resistance, which reduces the ability to cure many common acute infections compounded by a lack of having real alternative treatments in development. [10] [15, 16] and in the context of infectious disease prevention cost-effectiveness analysis is often used as a means to make informed decisions. [17, 18] Vaccination is in several ways a special health care intervention. [14] 
Social Impact
When it comes to priority-setting decisions and health care budget allocation, few will argue that costeffectiveness and economic welfare should be the only guiding principles. The societal value of a vaccination program beyond cost-effectiveness and economic welfare is also in part determined by its impact on other objectives of public policy, such as promoting health equity, sustaining public goods, and stimulating social integration. Depending on the specific context, vaccination programs can play an important positive or negative role in achieving these goals.
Promoting Health Equity
In the most recent decades, health equity--fairness in the distribution of health within a population--has "Luyten_2015-1088R.1_with_sbd_comments.docx" 12/15; lw 12/21; lw to dl 12/21; dl to sd 12/23; sd 12/23; lw to au 12/28; become an increasingly important social policy objective.
Vaccination programs can affect equity on two levels: between socioeconomic groups and between generations.
Both across and within country borders, along several axes of social stratification (e.g. education, income, occupation), it is systematically observed that the better-off population have better health prospects than the worse-off population. [29] There is a wide consensus that addressing this "social gradient" in health status should be a policy priority. However, affecting the social gradient presents obstacles, since it can be hard to identify the specific areas where action is most needed. Moreover, there is substantial evidence that many other health conditions (or even inequalities in wealth "Luyten_2015-1088R.1_with_sbd_comments.docx" 12/15; lw 12/21; lw to dl 12/21; dl to sd 12/23; sd 12/23; lw to au 12/28; and well-being) later in life (part of which will again qualify as being inequitable) are related to a bad start in childhood, [32] for example, through experiencing a severe episode of an infection, such as childhood meningitis or congenital rubella syndrome. A general recommendation of the WHO's commission on social determinants of health is, therefore, to strengthen the role of prevention, [33] and several authors argue that vaccination should be a priority in this. [34] But equity can also be relevant on an intergenerational level. The benefits, risks, and opportunity costs of a vaccination program are not necessarily fairly spread over different age groups and generations. Examples include disease-eradication programs where the benefits potentially extend to infinity, whereas risks and costs have to be incurred in the present; [35] "altruistic" vaccination (for instance, annual influenza vaccination in children that substantially decreases the risk of influenza in all age groups); and "egocentric" vaccination, which yields health gains in one generation but risks to induce health losses in another (for instance, childhood varicellazoster virus vaccination, which may decrease chickenpox in children but simultaneously increase shingles in adults and the elderly [36, 37] are given an equal value, regardless of whether they improve health equity, widen disparities even further (for example, by improving the health of better-off groups only), or harm the rightful interests of particular generations or age groups.
Sustaining The Public Good Of Herd Immunity
Herd immunity is the disease protection that those individuals in a population who are immune offer to the remaining susceptible ones. It arises as a consequence of the reduced circulation of a pathogen that is observed when more and more individuals become immune, either through having experienced an infection or through vaccination. [38] This herd immunity is an important way of protecting two groups of individuals who are unable to protect No one can be 100 percent certain that a vaccine he or she receives will work for him or her. In other words, herd immunity is an important benefit to everyone at any time. As we have all been children, and we expect to be old one day, and as we cannot be certain about our protection in the lifetime in between, we all benefit from herd immunity at different stages in our lifetime.
It should be seen as a safety net for unfortunate individuals, an essential second tier of infectious disease prevention.
This herd immunity should be considered as a "public good." [39, 40] It offers a substantial benefit to the entire population, but establishing and maintaining it requires collective action. This dependence on collective
effort makes a public good vulnerable, difficult to establish, and demanding to sustain. In the case of herd immunity, it requires broad support and dedication from the population to collectively undergo short-run sacrifices (costs and possible adverse effects from vaccinations) for more long-term and less visible herd immunity benefits. At the same time, on an individual level, people will have an incentive to "free ride" on the efforts of others: Let others become vaccinated and risk adverse effects and then take advantage of their efforts. [40] A key responsibility of public policy is to establish these public goods but also, once they are there, to manage the complex social dynamics that are involved in sustaining them. On the other hand, the opposite is also conceivable. [55, 56] Vaccination programs targeted specifically at these minorities could be perceived as discriminatory, by the target group who may feel unfairly singled out for vaccination or by the majority who has to pay more for the vaccine. Or, it could reinforce stigmatizing stereotypes that minority groups are responsible for the transmission of particular diseases in the community.
These subtleties affect the broader social impact of a program but are neglected in an appraisal based on cost-effectiveness or broader economic impact.
Conclusion
In a context of increasingly strained health budgets, in which cost-effectiveness analysis and comparative effectiveness research have become influential drivers of funding decisions (especially in Europe but increasingly in the United States as well), it is important to correctly understand the full contribution vaccination programs offer to the community and the extent to which this value is over-or underestimated in summary measures such as cost per QALY. (14, (19) (20) (21) (22) (23) (24) (25) (26) (27) . In this article, we argued that vaccination programs also have a special relationship with particular objectives of social policy.
An important but admittedly difficult challenge for health technology assessment and appraisal is to expand existing methods so that they manage to include these broader, complex, and often multidimensional effects. [57] However, in absence of more complete evaluation frameworks, decision makers should be aware of the social benefits and costs of vaccination that are excluded.
